Skip to main content

Table 2 Treatment regimens and emetogenisity

From: Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome

Emetogenisity Index of anti-emetic guideline Regimen Number
Minimal (n = 7) Early; (−), Delayed; (−) Tmab + VNR 2
Tmab 2
VNR 1
MTX + VCR + PSL 1
temsirolimus 1
Low (n = 38) Early; DEX, Delayed; (−) GEM 8
S-1 + GEM 1
nab-PTX + GEM 1
nab-PTX 3
Tmab + PTX 2
PTX 1
DTX + S-1 2
DTX + EMP 1
DTX + PSL 4
DTX 9
eribulin 1
Bmab + sLV5FU2 1
sLV5FU2 3
VTD 1
Moderate (n = 17) Early; NK1RA + 5-HT3RA + DEX, or 5-HT3RA + DEX, Delayed; NK1RA + 5-HT3RA + DEX, or 5-HT3RA + DEX Bmab + CBDCA + PTX 3
Pmab + FOLFOX6 2
Bmab + CapeOX 1
CapeOX 3
SOX 1
Bmab + FOLFIRI 1
Bmab + IRIS 1
IRIS 2
CPT-11 2
VCD 1
High (n = 11) Early; NK1RA + 5-HT3RA + DEX, Delayed; NK1RA + 5-HT3RA + DEX CDDP + CPT-11 4
FEC 2
EC 2
R-CHOP 3
  1. Tmab; Trastuzumab, VNR; vinorelbine, MTX; Methotrexate, VCR; Vincristine, PSL; Prednisolone, GEM; Gemcitabine, nab-PTX; nab-Paclitaxel, DTX; Docetaxel, EMP; estramustine, Bmab; Bevacizumab, sLV5FU2; simplified biweekly 5-FU & leucovorin, VTD; bortezomib, thalidomide, dexamethasone, CBDCA; Carboplatin, FOLFOX6; combination of Oxaliplatin and 5FU, CapeOX; capecitabine plus intermittent oxaliplatin, SOX; S-1 plus intermittent oxaliplatin, FOLFIRI; combination of Irinotecan and 5FU IRIS; CPT-11; Irinotecan, VCD; bortezomib, Cyclophosphamide, dexamethasone, CDDP; Cisplatin, FEC; 5FU, Epirubicin, Cyclophosphamide, EC; Epirubicin, Cyclophosphamide, R-CHOP; Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.